USE OF THE LIPOID OPTIMIZATION TOOL (LOT) TO ACHIEVE VARIOUS LDL TARGETS IN COMMUNITY PRACTICE

Authors: J. Niznick, C. Boutin, Suzanne Dugas
Ottawa Cardiovascular Centre (OCC), Ottawa, Ontario, Canada

Background (Objectives)
Lipid optimization has the potential to significantly reduce cardiovascular events and CHD death in various at risk populations. Failure to reach LDL target is commonplace and compromises cardiovascular outcomes. Our objective was to audit the effectiveness of the Lipid Optimization Tool as available on www.cvtoolbox.com, in achieving dyslipidemia control measured as LDL target achievement, in the high volume community practice at OCC.

Methods
OCC provides comprehensive follow-up to approximately 27,000 cardiovascular patients and structured lipid management and Telemonitoring for approximately 7000 dyslipidemia patients. The LOT has been used to guide lipid management at OCC since 1999. LOT flow sheets for patients of the 9 OCC specialists (6 cardiologists and 3 internists) were sequentially analyzed from July to December 2005. LDL control rates were calculated for the current Canadian Working Group (CWG) targets of 4.5 mmol/L for low risk (LR), 3.5 mmol/L for moderate risk (MR) and 2.5 mmol/L for high risk (HR) patients as well as the anticipated revised CWG LDL HR target of 2.0 mmol/L and the optional very high risk (VHR) NCEP ATP-III LDL target of 1.8 mmol/L.

Results
Data was collected on 963 patients; 78 LR, 87 MR, 62 HR and 736 VHR. LDL control rates were LR 94% (target < 4.5 mmol/L), MR 77% (target < 3.5 mmol/L), HR 68% (target < 2.5 mmol/L) and VHR 81% (target < 2.5 mmol/L), 59% (target < 2.0 mmol/L) and 46% (target 1.8 mmol/L).

Conclusions
Use of the LOT management protocol in contemporary community practice at OCC achieves amongst the best lipid control rates in the world.

Funding: Dyslipidemia management at OCC is supported by unrestricted grants from AstraZeneca, Merck Frosst and Pfizer.

www.cvtoolbox.com
Lipid Optimization Tool

Secondary Prevention % LDL (millimoles/L) change to reach LDL target by risk category

<table>
<thead>
<tr>
<th>Approach</th>
<th>LDL-C (mg/dL)</th>
<th>% Change</th>
<th>Initial Target</th>
<th>% Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low Risk</td>
<td>120-159</td>
<td>-10%</td>
<td>100</td>
<td>-15%</td>
</tr>
<tr>
<td>Moderate Risk</td>
<td>160-189</td>
<td>-15%</td>
<td>130</td>
<td>-20%</td>
</tr>
<tr>
<td>High Risk</td>
<td>190+</td>
<td>-20%</td>
<td>100</td>
<td>-25%</td>
</tr>
</tbody>
</table>

LDL-C, HDL-C, TRIGR, PT/TH, ALP

LDL: Low-density lipoprotein
HDL: High-density lipoprotein
TRIGR: Triglycerides
PT/TH: Prothrombin time
ALP: Alkaline phosphatase

Lipid Optimization Tool

© Continuing Medical Implementation Inc. March 2005

Statin Cost Efficacy

© Continuing Medical Implementation Inc. May 2006